

DAFTAR PUSTAKA

1. Fortuna G, Brennan MT. Systemic lupus erythematosus. Epidemiology, pathophysiology, manifestations, and management. Vol. 57, *Dental Clinics of North America*. 2013. p. 631–55.
2. Navarra S V., Leynes M. Infections in systemic lupus erythematosus. Vol. 19, *Lupus*. 2010. p. 1419–24.
3. Hamijoyo L, Candrianita S, Rahmadi AR, Dewi S, Darmawan G, Suryajaya BS, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. *Lupus*. 2019 Nov 1;28(13):1604–9.
4. Erdozain JG, Ruiz-Irastorza G, Egurbide M V., Martinez-Berriotxo A, Aguirre C. High risk of tuberculosis in systemic lupus erythematosus? *Lupus*. 2006;15(4):232–5.
5. 2020 W. Global Tuberculosis Report : Executive Summary 2020. World Health Organization. 2020;1(1).
6. Prabu VNN, Agrawal S. Systemic lupus erythematosus and tuberculosis: A review of complex interactions of complicated diseases. Vol. 56, *Journal of Postgraduate Medicine*. Medknow Publications and Media Pvt. Ltd; 2010. p. 244–50.
7. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. *Ann Rheum Dis*. 2002;61(3).
8. Hamijoyo L, Sahiratmadja E, Ghassani NG, Darmawan G, Susandi E, van Crevel R, et al. Tuberculosis among Patients with Systemic Lupus Erythematosus in Indonesia: a Cohort study 1 2. Available from: <https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofac201/6567503>
9. Yin Mok M, Mao Chan T. Tuberculosis in Systemic Lupus Erythematosus in an Endemic Area and the Role of Isoniazid Prophylaxis During Corticosteroid Therapy [Internet]. 2005. Available from: www.jrheum.org
10. Wang P, Pradhan K, Zhong X bo, Ma X. Isoniazid metabolism and hepatotoxicity. Vol. 6, *Acta Pharmaceutica Sinica B*. Chinese Academy of Medical Sciences; 2016. p. 384–92.
11. Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. *Tuberculosis*. 2019;116.

12. AIDSinfo. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. October 28, 2014. AIDSinfo. 2016;
13. Klein DJ, Boukouvala S, McDonagh EM, Shuldiner SR, Laurieri N, Thorn CF, et al. PharmGKB summary: Isoniazid pathway, pharmacokinetics. *Pharmacogenet Genomics*. 2016 Sep 1;26(9):436–44.
14. He Y, Sawalha AH. Drug-induced lupus erythematosus: An update on drugs and mechanisms. Vol. 30, *Current Opinion in Rheumatology*. 2018.
15. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: Then and now. Vol. 81, *British Journal of Clinical Pharmacology*. Blackwell Publishing Ltd; 2016. p. 1030–6.
16. Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? Vol. 14, *Expert Opinion on Drug Metabolism and Toxicology*. Taylor and Francis Ltd; 2018. p. 59–82.
17. Mugabo P, Shafick Hassan M, Slaughter R. Acute Pharmacokinetics of First Line Anti-tuberculosis Drugs in Patients with Pulmonary Tuberculosis and in Patients with Pulmonary Tuberculosis Co-infected with HIV. Vol. 8, *Journal of US-China Medical Science*. 2011.
18. Sundell J, Bienvenu E, Janzén D, Birgersson S, Äbelö A, Ashton M. Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. *Clin Pharmacol Ther*. 2020 Jul 1;108(1):73–80.
19. Alfarisi O, Mave V, Gaikwad S, Sahasrabudhe T, Ramachandran G, Kumar H, et al. Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. *Antimicrob Agents Chemother*. 2018;62(11).
20. Barliana MI, Kusuma ASW, Insani WN, Alfian SD, Diantini A, Mutakin M, et al. Genetic variation of ABCB1 (rs1128503, rs1045642) and CYP2E1 rs3813867 with the duration of tuberculosis therapy: a pilot study among tuberculosis patients in Indonesia. *BMC Res Notes*. 2021 Dec 1;14(1).
21. Tang K, Li X, Xing Q, Li W, Feng G, He L, et al. Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in Chinese Han populations from four different geographic areas of Mainland China. *Genomics*. 2010 Apr;95(4):224–9.
22. Tang S, Lv X, Zhang Y, Wu S, Yang Z, Xia Y, et al. Cytochrome P450 2E1 Gene Polymorphisms/Haplotypes and Anti-Tuberculosis Drug-Induced Hepatitis in a Chinese Cohort. *PLoS One*. 2013 Feb 27;8(2).
23. Liao LH, Zhang H, Lai MP, Chen SL, Wu M, Shen N. Single-nucleotide polymorphisms and haplotype of CYP2E1 gene associated with systemic

- lupus erythematosus in Chinese population [Internet]. 2011. Available from: <http://arthritis-research.com/content/13/1/R11>
24. Santos EA, Gonçalves JCS, Fleury MK, Kritski AL, Oliveira MM, Velasque LS, et al. Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST. *Brazilian Journal of Infectious Diseases*. 2019 Nov 1;23(6):381–7.
 25. Chen K, Guo R, Wei C. Synonymous mutation rs2515641 affects CYP2E1 mRNA and protein expression and susceptibility to drug-induced liver injury. *Pharmacogenomics*. 2020 May 1;21(7):459–70.
 26. Teixeira RLDF, Morato RG, Cabello PH, Muniz LMK, Moreira A da SR, Kritski AL, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. *Mem Inst Oswaldo Cruz*. 2011;106(6).
 27. Putri RN, Setiawan D. Optimasi Prediksi Penyakit Systemic Lupus Erythematosus Menggunakan Algoritma Particle Swarm Optimization. *TechnoCom*. 2020;19(1).
 28. Fors Nieves CE, Izmirly PM. Mortality in Systemic Lupus Erythematosus: an Updated Review. Vol. 18, *Current Rheumatology Reports*. Current Medicine Group LLC 1; 2016.
 29. Arora S, Isenberg DA, Castrejon I. Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. *Arthritis Care Res (Hoboken)*. 2020;72(S10):27–46.
 30. Balbi GGM, MacHado-Ribeiro F, Marques CDL, Signorellia F, Levy RA. The interplay between tuberculosis and systemic lupus erythematosus. Vol. 30, *Current Opinion in Rheumatology*. Lippincott Williams and Wilkins; 2018. p. 395–402.
 31. Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Vol. 22, *Lupus*. 2013. p. 1286–94.
 32. Brassard P, Kezouh A, Suissa S. Antirheumatic Drugs and the Risk of Tuberculosis [Internet]. Available from: <https://academic.oup.com/cid/article/43/6/717/326987>
 33. Bhattacharya PK, Jamil M, Roy A, Talukdar KK. SLE and tuberculosis: A case series and review of literature. Vol. 11, *Journal of Clinical and Diagnostic Research*. *Journal of Clinical and Diagnostic Research*; 2017. p. OR01–3.
 34. Oku K, Hamijoyo L, Kasitanon N, Li MT, Navarra S, Morand E, et al. Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. Vol. 24, *International Journal of Rheumatic Diseases*. John Wiley and Sons Inc; 2021. p. 880–95.

35. Fan J, de Lannoy IAM. Pharmacokinetics. Vol. 87, Biochemical Pharmacology. 2014. p. 93–120.
36. Conte JE, Golden JA, McQuitty M, Kipps J, Duncan S, McKenna E, et al. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. *Antimicrob Agents Chemother.* 2002;46(8).
37. Wadhwa RR, Cascella M. Steady State Concentration. *StatPearls.* 2020.
38. Mark AB. What is Steady-State Concentration in Pharmacokinetics? *Nuventra pharma sciences* 2020;
39. Hamijoyo L, Sahiratmadja E, Ghassani NG, Darmawan G, Susandi E, Van Crevel R, et al. Tuberculosis among Patients with Systemic Lupus Erythematosus in Indonesia: a Cohort study 1 2. Available from: <https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofac201/6567503>
40. Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, et al. Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. *Clin Pharmacokinet.* 2019 Nov 1;58(11):1445–54.
41. Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, et al. Isoniazid’s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. *Journal of Infectious Diseases.* 2007;195(2).
42. Evans WE, McLeod HL. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects. *New England Journal of Medicine.* 2003;348(6).
43. Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: The genetics of variable drug responses. *Circulation.* 2011;123(15).
44. Desta Z, Soukhova N v., Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A. *Antimicrob Agents Chemother.* 2001;45(2).
45. Hamijoyo L, Candrianita S, Rini IA, Sutedja E, Setiabudiawan B, Sahiratmadja E. N-acetyltransferase 2 (NAT2) acetylator status among systemic lupus erythematosus patients from a tuberculosis endemic area in Bandung, Indonesia. *Indonesian Biomedical Journal.* 2019;11(2):175–81.
46. Xing S, Wang Y, He X, Yang W, Hu Q, He Y, et al. CYP2C8 and CYP2E1 genetic variants increase risk of tuberculosis in northwest Chinese Han population. *Infection, Genetics and Evolution.* 2021;95.
47. Roy P das, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Vol. 9, *Pharmacogenomics.* 2008.
48. Requena-Méndez A, Davies G, Waterhouse D, Ardrey A, Jave O, López-Romero SL, et al. Effects of dosage, comorbidities, and food on Isoniazid

- pharmacokinetics in peruvian tuberculosis patients. *Antimicrob Agents Chemother.* 2014;58(12).
49. Barliana MI, Afifah NN, Amalia R, Hamijoyo L, Abdulah R. Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine. Vol. 13, *Frontiers in Pharmacology.* Frontiers Media S.A.; 2022.
 50. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, et al. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. *Antimicrob Agents Chemother.* 2013;57(7).
 51. Ruslami R, Gafar F, Yunivita V, Parwati I, Ganiem AR, Aarnoutse RE, et al. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. *Arch Dis Child.* 2022 Jan 1;107(1):70–7.
 52. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. *Comput Methods Programs Biomed.* 2010;99(3).
 53. Chen K, Guo R, Wei C. Synonymous mutation rs2515641 affects CYP2E1 mRNA and protein expression and susceptibility to drug-induced liver injury. *Pharmacogenomics.* 2020;21(7).
 54. Barliana MI, Kusuma ASW, Insani WN, Alfian SD, Diantini A, Mutakin M, et al. Genetic variation of ABCB1 (rs1128503, rs1045642) and CYP2E1 rs3813867 with the duration of tuberculosis therapy: a pilot study among tuberculosis patients in Indonesia. *BMC Res Notes* [Internet]. 2021;14(1):1–7. Available from: <https://doi.org/10.1186/s13104-021-05711-8>
 55. Perwitasari DA, Darmawan E, Mulyani UA, Vlies P Van Der, Alffenaar JWC, Atthobar J, et al. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in Indonesian tuberculosis patients. *Int J Mycobacteriol.* 2018 Oct 1;7(4):380–6.
 56. Liao LH, Zhang H, Lai MP, Chen S Le, Wu M, Shen N. Single-nucleotide polymorphisms and haplotype of CYP2E1 gene associated with systemic lupus erythematosus in Chinese population. *Arthritis Res Ther* [Internet]. 2011;13(1):R11. Available from: <http://arthritis-research.com/content/13/1/R11>
 57. Xing S, Wang Y, He X, Yang W, Hu Q, He Y, et al. CYP2C8 and CYP2E1 genetic variants increase risk of tuberculosis in northwest Chinese Han population. *Infection, Genetics and Evolution* [Internet]. 2021;95(August):105022. Available from: <https://doi.org/10.1016/j.meegid.2021.105022>
 58. Yu YY, Tsao SM, Yang WT, Huang WC, Lin CH, Chen WW, et al. Association of drug metabolic enzyme genetic polymorphisms and adverse

- drug reactions in patients receiving rifapentine and isoniazid therapy for latent tuberculosis. *Int J Environ Res Public Health*. 2020;17(1):1–9.
59. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunegoro H, Ascobat P, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. *Antimicrob Agents Chemother*. 2013;57(8):3614–9.
 60. Peloquin CA, Jaresko GS, Yong CL, Keung ACF, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. *Antimicrob Agents Chemother*. 1997;41(12):2670–9.
 61. Aït Moussa L, El Bouazzi O, Serragui S, Soussi Tanani D, Soulaymani A, Soulaymani R. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis. *Ther Adv Drug Saf*. 2016;7(6):239–47.
 62. Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. *Curr Opin Rheumatol*. 2000;12(5):379–85.
 63. Van Oosterhout JJ, Dzinjalama FK, Dimba A, Waterhouse D, Davies G, Zijlstra EE, et al. Pharmacokinetics of antituberculosis drugs in HIV-positive and HIV-negative adults in Malawi. *Antimicrob Agents Chemother*. 2015;59(10):6175–80.
 64. Donald PR, Parkin DP, Seifart HI, Schaaf HS, Van Helden PD, Werely CJ, et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. *Eur J Clin Pharmacol*. 2007;63(7):633–9.
 65. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, et al. Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. *Antimicrob Agents Chemother*. 2007;51(7):2329–36.
 66. Chen B, Shi HQ, Feng MR, Wang XH, Cao XM, Cai WM. Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population. *Front Pharmacol*. 2022;13(July):1–13.
 67. Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for *Mycobacterium tuberculosis*. *Journal of Antimicrobial Chemotherapy*. 2009;64(4):786–93.
 68. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. *European Journal of Clinical Microbiology and Infectious Diseases*. 2004;23(4):243–55.
 69. Geib AJ, Shannon MW. Isoniazid. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, Fourth Edition. 2007 Jan 1;919–25.

70. Hernández-González O, Zarazúa S, Veytia-Bucheli JI, González-Chávez MM, Rodríguez-Pinal CJ, Medellín-Garibay SE, et al. Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis. *J Sep Sci.* 2021;44(2):521–9.
71. Holford N, Yim DS. Clearance. *Transl Clin Pharmacol.* 2015;23(2):42–5.
72. Sarma GR, Kailasam S, Nair NG, Narayana AS, Tripathy SP. Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. *Antimicrob Agents Chemother.* 1980;18(5):661–6.
73. van Matre ET, Satyanarayana G, Page RL, Levi ME, Lindenfeld J, Mueller SW. Pharmacokinetic drug–drug interactions between immunosuppressant and anti-infective agents: Antimetabolites and corticosteroids. *Ann Transplant.* 2018;23:66–74.
74. Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. *Pharmacogenomics.* 2009;10(9):1433–45.
75. Santos NPC, Callegari-Jacques SM, Dos Santos AKCR, Silva CA, Vallinoto ACR, Fernandes DCRO, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. *International Journal of Tuberculosis and Lung Disease.* 2013;17(4):499–504.
76. Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. *Journal of Gastroenterology and Hepatology (Australia).* 2013;28(8):1368–74.
77. Chamorro JG, Castagnino JP, Aidar O, Musella RM, Frías A, Visca M, et al. Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity. *Pharmacogenet Genomics.* 2017;27(10):363–71.
78. Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, et al. The incidence of liver injury in uyghur patients treated for TB in Xinjiang Uyghur Autonomous Region, China, and its association with hepatic enzyme polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1. *PLoS One.* 2014;9(1):1–8.
79. Huang YS, Chern H Der, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. *Hepatology.* 2003;37(4):924–30.

80. Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, et al. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. *Eur J Clin Pharmacol*. 2011;67(2):121–7.
81. An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. *Clin Exp Pharmacol Physiol*. 2012;39(6):535–43.
82. Richardson M, Kirkham J, Dwan K, Sloan DJ, Davies G, Jorgensen AL. CYP genetic variants and toxicity related to anti-tubercular agents: A systematic review and meta-analysis. *Syst Rev*. 2018;7(1).
83. Chan SL, Chua APG, Aminkeng F, Chee CBE, Jin S, Loh M, et al. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. *PLoS One*. 2017;12(10):1–16.
84. Wang T, Yu HT, Wang W, Pan YY, He LX, Wang ZY. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in chinese tuberculosis patients. *Journal of International Medical Research*. 2010;38(3):977–86.
85. Tang SW, Lv XZ, Zhang Y, Wu SS, Yang ZR, Xia YY, et al. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: A nested case-control study. *J Clin Pharm Ther*. 2012;37(5):588–93.
86. Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. *Pharmacogenomics*. 2009;10(11):1767–79.
87. Costa GNO, Magno LAV, Santana CVN, Konstantinovas C, Saito ST, Machado M, et al. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. *Mol Diagn Ther*. 2012;16(4):241–50.
88. Lee SW, Chung LSC, Huang HH, Chuang TY, Liou YH, Wu LSH. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. *International Journal of Tuberculosis and Lung Disease*. 2010;14(5):622–6.
89. Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda FM, Frías A, et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. *Journal of Gastroenterology and Hepatology (Australia)*. 2013;28(2):323–8.
90. Richardson M, Kirkham J, Dwan K, Sloan DJ, Davies G, Jorgensen AL, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. *International Journal of Tuberculosis and Lung Disease*. 2013;14(1):293–305.